Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey

Creative Commons License

Reiner Z., De Backer G., Fras Z., Kotseva K., Tokgozoglu L., Wood D., ...Daha Fazla

ATHEROSCLEROSIS, cilt.246, ss.243-250, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 246
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.atherosclerosis.2016.01.018
  • Dergi Adı: ATHEROSCLEROSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.243-250
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: Since dyslipidaemia is one of the most important risk factors for coronary heart disease (CHD), lowering of LDL-cholesterol (LDL-C) causes significant reduction in morbidity and mortality, particularly in patients with established CHD. The aim of this survey was to assess how statins were prescribed in CHD patients at discharge after a coronary event from hospitals throughout Europe and how the intake of these drugs was reported by the patients when they were seen more than one year later in relationship with their achieved LDL-C levels.